依达拉奉对急性脑梗死患者高敏C反应蛋白及预后的影响

Effect of Edaravone on High Sensitivity C-reactive Protein and Prognosis in Patients with Acute Cerebral Infarction

目的探讨依达拉奉对急性脑梗死(ACI)患者高敏C反应蛋白(hsCRP)含量及预后影响。方法选择ACI患者72例,随机分为治疗组与对照组各36例,在常规治疗的基础上,治疗组予依达拉奉30 mg静脉滴注,每日2次;对照组予奥拉西坦4.0 g静脉滴注,每日1次,疗程7 d。检测血清hsCRP、神经功能缺损和日常生活能力。结果治疗组在治疗后第7、14天hsCRP水平明显低于对照组(P<0.05);第7、14天欧洲脑卒中评分量表评分高于对照组,第7、14、30、90天日常生活活动量表评分均高于对照组(P<0.05)。结论依达拉奉可明显减轻ACI患者炎性反应,改善缺损神经功能和日常生活能力。

Objective To observe the clinical effects of edaravone on high sensitivity C-reactive protein（hsCRP）and prognosis in patients with acute cerebral infarction（ACI）.Methods 72 patients with ACI were randomly divided into study group and control group（n=36）,on the basis of conventional treatment,study group were treated with edaravone of 30 mg intravenously（twice a day）,control group were treated with oxiracetam of 4.0 g intravenously（once a day）respectively.All treated for 7 days.The level of serum hsCRP was measured by immunomephelometry pretreatment and on the 7th day and the 14th day post-treatment;the European stroke scale（ESS）and activity of daily living（ADL）were scored.Results The level of serum hsCRP on the 7th day and the 14th day post-treatment in the study group was significantly decreased than that in the control group（P0.05）,the score of ESS on the 7th,14th,the score of ADL on the 7th,14th,30th and 90th day in the study group was significantly increased than that in the control group（P0.05）.Conclusion Edaravone can decrease the level of inflammatory reaction,improve impaired neurologic function and daily living activity.